AUTHORS
Matthew J. Cortese, MD, MPH, Victoria Otero, MD2, Madhav Seshadri, MD3, Daniel Huang, PharmD, MPH4, Julia Ma, MPH5, Debbie Adkins, PhD, CStat6, Dipen Patel, PhD7
AFFILIATIONS
1 Roswell Park Comprehensive Cancer Center, Buffalo, United States
2 AstraZeneca, Gaithersburg, United States
3 UCSF Health, San Francisco, California, United States
4 AstraZeneca, Gaithersburg, United States
5 AstraZeneca, Mississauga, Ontario, Canada
6 AstraZeneca, Cambridge, United Kingdom
7 AstraZeneca, Gaithersburg, United States
ABSTRACT
Background: Acalabrutinib and zanubrutinib are 2nd generation covalent Bruton tyrosine kinase inhibitors (cBTKis) used as standard first-line (1L) treatments for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Although both agents have demonstrated favorable safety profiles compared to first-generation cBTKi ibrutinib in clinical trials, no head-to-head randomized controlled trial has directly compared acalabrutinib and zanubrutinib. This study evaluated cardiovascular- and infection-related medical events of interest (MEI) among patients with CLL/SLL initiating 1L acalabrutinib or zanubrutinib monotherapy using two large US administrative claims databases.
Methods: Adults with CLL/SLL initiating 1L acalabrutinib or zanubrutinib monotherapy were identified from the Optum Clinformatics® Data Mart (January 1, 2023–September 30, 2025) and IQVIA PharMetrics® Plus (January 1, 2023–October 31, 2025) databases. Patients required ≥6 months of continuous enrollment before treatment initiation and an index date ≥3 months before the database-specific cutoff. Patients with another primary malignancy, or clinical trial participation were excluded. The index date was the first observed claim for cBTKi. Inverse probability of treatment weighting (IPTW) was used to adjust for baseline and disease characteristics, such as index year, age, and National Cancer Institute (NCI) comorbidity index. Outcomes included incidence (cardiovascular- and infection-related) and exposure-adjusted incidence rates (EAIRs; events per 100 person-years) of MEIs. Hazard ratios (HR) for time to first MEI and 95% confidence intervals (CI) were estimated using Cox proportional hazard models.
Results: The study included 1,758 patients from Optum (acalabrutinib, n=1,196; zanubrutinib, n=562) and 2,683 patients from IQVIA (acalabrutinib, n=1,750; zanubrutinib, n=933). Following IPTW, baseline characteristics were similar between treatment cohorts. In Optum, the mean age was approximately 75 years, 38% were female, >90% had Medicare coverage, and the mean comorbidity index was 1.1 and 1.0 in the acalabrutinib and zanubrutinib cohorts, respectively. Median follow-up was 17.0 months for acalabrutinib and 16.4 months for zanubrutinib. In IQVIA, the mean age was 69 years, 37% were female, >50% had Medicare coverage, >34% had commercial insurance, and the mean NCI comorbidity index was 1.0 and 1.1, respectively. Median follow-up was 17.0 months for acalabrutinib and 16.4 months for zanubrutinib. Following IPTW, baseline cardiovascular- and infection-related comorbidities, including atrial fibrillation, arrhythmia, hypertension, bleeding, and infection, were comparable between cohorts and all subsequent results are reported from the weighted cohorts. Incidence rates were numerically lower with acalabrutinib for hypertension (Optum, 13.5% vs 15.3%; IQVIA, 13.7% vs 15.0%) and bleeding (Optum, 10.2% vs 12.8%; IQVIA, 9.9% vs 10.3%). Infection incidence was lower with acalabrutinib in Optum (24.1% vs 30.1%) but identical between arms in IQVIA (22.3% vs 22.3%). EAIR were directionally consistent with these proportions, although differences were not statistically significant for hypertension (Optum: 28.1 vs 38.9; HR, 0.76; 95% CI, 0.58–1.01; IQVIA: 28.0 vs 33.5; HR, 0.84; 95% CI, 0.67–1.03) or bleeding (Optum: 7.57 vs 10.50; HR, 0.74; 95% CI, 0.54–1.01; IQVIA: 8.36 vs 8.98; HR, 0.94; 95% CI, 0.72–1.22). Other Cardiovascular MEI (atrial fibrillation, arrhythmia, stroke, congestive heart failure, myocardial infarction) were similar between acalabrutinib and zanubrutinib. Infection findings differed between databases: acalabrutinib was associated with a lower rate in Optum (23.36 vs 32.60; HR, 0.74; 95% CI, 0.60–0.91), whereas rates were comparable in IQVIA (23.82 vs 25.25; HR, 0.96; 95% CI, 0.81–1.14).
Conclusion: In this comparative real-world analysis of two large US administrative claims databases, acalabrutinib and zanubrutinib demonstrated broadly comparable cardiovascular safety profiles, with consistent findings observed across both data sources. Hypertension and bleeding were numerically lower with acalabrutinib across both databases, although these differences were not statistically significant. Longer-term follow-up and analyses using electronic health records are warranted to better understand the clinical rationale for treatment patterns and to further characterize comparative safety outcomes.
DISCLOSURES
Matthew J. Cortese, MD, MPH: Adaptive Biotechnologies - Honoraria; Abbvie - Honoraria; SignifyMD - Honoraria; MJH Events - OncLive/PER - Honoraria; Bristol Myers Squibb - Honoraria; AstraZeneca - Honoraria; Binaytara Foundation - Honoraria; Curio Science - Honoraria; CCO/Decera - Honoraria; Merck - Research Funding; ADC Therapeutics - Consultancy (Includes expert testimony); Adaptive Biotechnologies - Consultancy (Includes expert testimony); Abbvie - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); Synthekine LLC - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Genmab - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony)